Serum and cervicovaginal IgG immune responses against α7 and α9 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination

Abstract

BackgroundCervical cancer associated with high risk-human papillomavirus (HR-HPV) infection is becoming the one of the most common female cancer in many sub-Saharan African countries. First-generation immigrant African women living in Europe are at-risk for cervical cancer, in a context of social vulnerability, with frequent lack of cervical cancer screening and HPV vaccination. ObjectiveOur objective was to address immunologically the issue of catch-up prophylactic HPV vaccination in first-generation African immigrant women living in France. MethodsIgG immune responses and cross-reactivities to α7 (HPV-18, -45 and -68) and α9 (HPV-16, -31, -33, -35, -52 and -58) HPV types, including 7 HR-HPV targeted by the Gardasil-9 ® prophylactic vaccine, were evaluated in paired serum and cervicovaginal secretions (CVS) by HPV L1-virus-like particles-based ELISA. Genital HPV were detected by multiplex real time PCR (Seegene, Seoul, South Korea).

In vitro inhibitory activity against HPV of the monoterpenoid zinc tetra-ascorbo-camphorate

“…Therefore, this method helps to assess the neutralizing activity of compounds against HPV [ 20 ]. In the present study, we have produced PsV for HPV-16 according to the recommendations stated by the papillomavirus vectors production protocol ( https://ccrod.cancer.gov/confluence/display/LCOTF/PseudovirusProduction ) edited by the Laboratory of Cellular Oncology of the Center for Cancer Research (National cancer institute, National Institute of Health, Rockville Pike, Bethesda, Maryland, USA), with minor adaptations, as we fully detailed previously elsewhere [ 6 ]. Briefly, the plasmid vector p16sheLL incorporating both L1 and L2 genes for HPV-16 was used to produce HPV-16-PsVs, as previously described [ 9 , 21 , 22 , 23 , 24 , 25 ].…”

“…The prophylactic vaccination with Gardasil-9® vaccine (Merck & Co. Inc., Kenilworth, NJ, USA) containing virus-like particles from HPV-6 and HPV-11, as well as two α7 (HPV-18 and HPV-45) and five α9 (HPV-16, -31, -33, -52 and -58) high-risk HPV, constitutes one of the main strategies against cervical cancer [ 5 , 6 ], and is subsidized in underserved and poor countries by Global Alliance for Vaccines and Immunization [ 7 ]. Although the benefits of global HPV vaccination program are undeniable [ 7 ], prophylactic HPV vaccines do not protect against numerous nonvaccine HPV types associated with several HPV-related diseases and have low uptake due, in part, to high cost and cold chain storage requirements [ 8 ].…”